Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly

This study has been completed.
Information provided by (Responsible Party):
Bruno Geloneze, University of Campinas, Brazil Identifier:
First received: February 12, 2009
Last updated: March 7, 2013
Last verified: March 2013

Like most endocrine axes, the entero-insular axis is expected to go through an age-related physiological deterioration, what might contribute to special features of the elderly onset type 2 diabetes in comparison to middle-age.

Twenty four NGT volunteers will be evaluated by a meal tolerance test (MTT) for incretin hormone measurements, and by the hyperglycemic clamp followed by an arginine test for assessing the beta-cell function and the acute insulin response. Others parameters as body composition and basic biochemistry will be also evaluated at Laboratory of Investigation on Metabolism and Diabetes - LIMED / State university of Campinas, Brazil.

The characterization of the glucagon-like peptide-1 (GLP-1) production, dipeptidyl peptidase IV (DPP-IV) activity and/or endocrine pancreas incretin-response at aging, might be an interesting evidence to reinforce an incretin-based therapeutic approach for elderly onset type 2 diabetes.

Diabetes Mellitus, Type 2
Insulin Resistance

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly.

Further study details as provided by Bruno Geloneze, University of Campinas, Brazil:

Primary Outcome Measures:
  • Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index [ Time Frame: within 1 month from screening visit ]
    Insulin sensitivity index calculated as HOMA-IR = (Glucose * Insulin) / 22.5, where glucose is mmol/L and insulin is mili-units (mU)/L. Higher values indicate lower insulin sensitivity.

  • Glucose Infusion Rate [ Time Frame: within 1 month from screening visit ]
    Whole-body insulin sensitivity, as estimated by the mean glucose infusion rate corrected for fat-free mass(FFM){mg*[kg(FFM)^-1]*min*10} at last 60 min of 180-min hyperglycemic clamp

  • Adaptive Beta-cell Insulin Production. The Product of Meal Tolerance Test-derived Insulinogenic Index (IGI) for Clamp-derived Insulin Sensitivity Index (ISI) in Normoglycemic Subjects After 65 Years Old in Comparison With Middle-age Normoglycemic Subjects [ Time Frame: within 1 month from screening visit ]
    Beta-cell function was determinated as the beta-cell secretion measured by meal tolerance test adjusted by insulin sensitivity assessed by the hyperglycemic clamp test:Insulinogenic Index/Insulin Sensitivity Index adjusted by free fat mass

  • Distinctive Beta-cell Function From the Arginine Stimulation Test in Normoglycemic Subjects After Sixty-five Years Old in Comparison With Middle-age Normoglycemic Subjects. [ Time Frame: within 1 month from screening visit ]
    Distinctive beta-cell function as measured by the disposition index - based on the acute insulin response from the arginine stimulation test versus glucose infusion rate adjusted by free fat mass from hyperglycemic clamp - in normoglycemic subjects after sixty-five years old in comparison with middle-age normoglycemic subjects.

Secondary Outcome Measures:
  • Serum Dipeptidyl Peptidase IV (DPP-IV) Concentration [ Time Frame: within 1 month from screening visit ]
    measured in fasting serum sample by ELISA kit

  • GLP-1 Area Under the Curve (AUC) [ Time Frame: 1 month from screening visit ]
    Area under the curve of glucagon-like peptide (GLP-1) concentrations (measured by ELISA kit) from time 0 to 180 min during a standard meal tolerance test, calculated by the trapezoidal rule.

Biospecimen Retention:   Samples Without DNA
Sera and plasma

Enrollment: 24
Study Start Date: June 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Elderly NGT
Normoglycemic subjects 65-80 years old
Middle-age NGT
Middle-age normoglycemic subjects 35 to 50 years old.


Ages Eligible for Study:   35 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adult normoglycemic subjects

Inclusion Criteria:

  • Stable weight (< 5% variation) within the last three months
  • Age: 35 to 50 years old for middle-age group, and 65 to 80 years old for elderly group.
  • BMI: 20 to 29.9 kg/m2
  • Normal glucose tolerance (NGT) for groups Elderly and Middle-age

Exclusion Criteria:

  • Use of estrogen, progestogen or systemic corticosteroids.
  • Hepatic cirrhosis, renal failure or any clinical condition with impaired insulin sensitivity
  • Smoking
  • Obesity
  • Uncontrolled systemic or debilitating diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00843479

LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/Univeristy of Campinas (UNICAMP)
Campinas, SP, Brazil
Sponsors and Collaborators
University of Campinas, Brazil
Principal Investigator: Bruno Geloneze, MD, PhD LIMED (Laboratory of Investigation of Metabolism and Diabetes)/GASTROCENTRO/Univeristy of Campinas (UNICAMP)
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bruno Geloneze, Dr. Bruno Geloneze, University of Campinas, Brazil Identifier: NCT00843479     History of Changes
Other Study ID Numbers: LIMED0006
Study First Received: February 12, 2009
Results First Received: October 4, 2011
Last Updated: March 7, 2013

Keywords provided by Bruno Geloneze, University of Campinas, Brazil:
diabetes mellitus, type 2
Insulin resistance
DPP-IV protein, human
Glucagon-Like Peptide 1
Gastric Inhibitory Polypeptide

Additional relevant MeSH terms:
Diabetes Mellitus
Insulin Resistance
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Gastric Inhibitory Polypeptide
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on May 25, 2017